Project Grant R01DE033520

Award Date 9/1/24
Completion Date 5/31/28
Dollars Obligated $1.8M
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This $557,606 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research by Harvard Medical School on cellular and molecular mechanisms of periodontal tissue regeneration. The project aims to characterize periodontal crestal stem cells, determine signaling pathways regulating their activation and differentiation during tissue repair, and evaluate the role of specific niche...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $157,500 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to The Ohio State University to conduct research on the cellular mechanisms regulating tooth development. The research aims to determine how the signaling molecule SEMA7A influences the mineralization of dentin, elongation of tooth roots, and innervation of teeth. The study will use global and conditional SEMA7A knockout mouse...
The federal Project Grant award R01DE033676, totaling $346,938.00, was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121). The grant supports research to understand how a novel GTPase regulator, known as DIN, governs the regenerative capacity of mesenchymal stem cells (MSCs) in murine teeth. The research aims to determine DIN's role in regulating MSC homeostasis during tissue turnover...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $421,800 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to Midwestern University. The purpose of this 3-year grant, with a start date of September 7, 2023, is to develop hybrid hydrogel-based dental adhesives that are less vulnerable to hydrolytic degradation compared to current methacrylate-based alternatives. The goal is to create a truly biomimetic dental adhesive that can not only...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $443,576 to the University of Washington to develop bioengineered 3D tooth germs for tooth regeneration research. The key objectives are to: 1) investigate how biomaterial composition and mechanical properties regulate stem cell renewal and support long-term growth of odontogenic epithelial stem cells and neural...
This $499,440 Project Grant awarded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) aims to develop and evaluate novel dental restoration materials that are more durable and have enhanced antimicrobial, protein-repellent, and therapeutic properties compared to existing methacrylate-based resin composites. The key objectives are to formulate biostable hybrid resin networks, incorporate multifunctional...
This $1,705,144 Project Grant awarded on August 12, 2024 by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) aims to develop novel therapies for periodontal disease regeneration. The key objectives are: Identifying cell surface markers to isolate and characterize human periodontal ligament stem cells expressing the PRX1 transcription factor (hPRX1-PCs), which have been shown to contribute to periodontal...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR, CFDA 93.121 Oral Diseases and Disorders Research) provides $1,403,398 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on head and neck squamous cell carcinoma (HNSCC). The project aims to utilize advanced imaging approaches to develop imaging-based biomarkers related to a hybrid epithelial/mesenchymal state within HNSCC tumors and its...
The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Program (CFDA 93.121), awarded a $1,865,330 Project Grant to the University of Alabama at Birmingham (UAB). The grant, titled "Structural and Functional Studies on the Glucosyltransferases of the Dental Caries Pathogen Streptococcus mutans," aims to determine the specific molecular mechanisms that drive the synthesis of soluble and insoluble glucans by the...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $591,378 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to Callentis Consulting Group LLC, a woman-owned small business. The funding supports the development of high-performance, bisphenol A (BPA)-free dental restoration composites with remineralization capabilities. The research, conducted in collaboration with the University of Colorado and New Mexico State University, aims to...

The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,849,232.90 Project Grant under the Oral Diseases and Disorders Research Program (CFDA 93.121) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to identify the cellular and molecular identity of genes and pathways defining dental mesenchymal cell differentiation and fate early in tooth development. The goal is to harness this information to develop potential therapeutics, with a focus on dentin regeneration. The project will run from September 1, 2024 to May 31, 2028. This research aims to address significant public health problems such as tooth agenesis, dentinogenesis imperfecta, caries, and fractures, which affect up to 30-40% of the global population and impose substantial costs. The research will build upon Massachusetts General Hospital's extensive expertise in biomedical research, clinical trials, and specialized medical countermeasure development services provided to various federal agencies.

Generated 7/8/25, 12:35 PM